Resources
Please contact us if you have any questions.
Public Health Agency HSC NI documents
UK Health Security Agency
Police Service Northern Ireland
Department of Health NI documents
- doh-regional-policy-restrictive-practices-hsc-nov-2023
- HSS MD 7 2025 Spring 2025 Covid-19 Booster Programme
- HSS MD 40 2024 letter- MHRA Drug ~ MedSafetyWeek November 2024 your Yellow Card report helps prevent future harm to others and improves patient safety
- HSS MD 39 2024 AUTUMN 2024 25 SEASONAL INFLUENZA AND COVID-19 VACCINATION PROGRAMMES FOR HEALTH AND SOCIAL CARE WORKERS
- Circular Providing Clarification Guidance on Roles and Responsibilities - Accessing Private Healthcare
- HSS(MD) 35 2024 - SEASONAL INFLUENZA VACCINATION PROGRAMME 2024 2025 - EXTENSION TO ALL HEALTH AND SOCIAL CARE WORKERS
- ADDENDUM HSS(MD) 34 2024 - COVID-19 AUTUMN 2024 BOOSTER VACCINATION PROGRAMME
- HSS MD 33 2024 SEASONAL INFLUENZA VACCINATION PROGRAMME 2024 2025
- HSS(MD) 24 2024 - INTRODUCTION OF UNIVERSAL RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINATION PROGRAMME FOR OLDER ADULTS AND DURING PREGNANCY FOR INFANT PROTECTION
- HSS(MD) 22 2024 - MEDICINE SUPPLY NOTIFICATION - PABRINEX® (VITAMINS B AND C) INTRAVENOUS AND INTRAMUSCULAR HIGH POTENCY SOLUTION FOR INJECTION AMPOULES
- HSS(MD) 21 2024 - MHRA DRUG SAFETY UPDATE – TOPIRAMATE (TOPAMAX) INTRODUCTION OF NEW SAFETY MEASURES, INCLUDING A PREGNANCY PREVENTION PROGRAMME
- HSSMD-20-2024-NEW-RESTRICTIONS-ON-USE-OF-PUBERTY-SUPPRESSING-HORMONES-PUBERTY-BLOCKERS-IN-GREAT-BRITAIN-–-INFORMATION-FOR-PRESCRIBERS-AND-PHARMACISTS-DISPENSING-DOCTORS
- ADDENDUM-TO-HSSMD-51-2023-FULL-PACK-DISPENSING-OF-VALPROATE-CONTAINING-MEDICINES
- HSSMD-19-2024-MHRA-Drug-Safety-Update-–-Topical-steroids-introduction-of-new-labelling-and-a-reminder-of-the-possibility-of-severe-side-effects-including-Topical-Steroid-Withdrawal-Reactions
- HSSMD-18-2024-NATIONAL-PATIENT-SAFETY-ALERT-SHORTAGE-OF-PANCREATIC-ENZYME-REPLACEMENT-THERAPY-PERT
- HSS-MD-15-2024-NATIONAL-PATIENT-SAFETY-ALERT-Shortage-of-Orencia-Clickject-125mg-1ml-solution-for-injection-pre-filled-pens
- HSS-MD-16-2024-HEPATITIS-C-TESTING-GUIDANCE
- TMSNI-Newsletter-LMcM-Letter-May-2024
- TMSNI-News-Issue1
- HSSMD-17-2024-END-OF-THE-2023-24-INFLUENZA-SEASON-AND-RELATED-ISSUES
- HSSMD-14-2024-MHRA-Drug-Safety-Update-Finasteride-and-Montelukast
- HSS-MD-12-2024-COVID-19-TREATMENTS-UPDATED-NICE-GUIDANCE-TA878-Nirmatrelvir-plus-ritonavir-sotrovimab-and-tocilizumab-for-treating-COVID-19
- HSSMD-10-2024-UPDATE-TO-COVID-19-TESTING-GUIDANCE-HSSMD-CIRCULARS-WITHDRAWN
- HSSMD-09-2024-NATIONAL-PATIENT-SAFETY-ALERT-–-SHORTAGE-OF-SALBUTAMOL-2.5MG-2.5ML-AND-5MG-2.5ML-NEBULISER-LIQUID-UNIT-DOSE-VIALS
- HSSMD-08-2024-MHRA-DRUG-SAFETY-UPDATE-–-PSEUDOEPHEDRINE-VERY-RARE-RISK-OF-POSTERIOR-REVERSIBLE-ENCEPHALOPATHY-SYNDROME-PRES-AND-REVERSIBLE-CEREBRAL-VASOCONSTRICTION-SYNDROME-RCVS
- HSSMD-07-2024-MHRA-DRUG-SAFETY-UPDATE-–-CODEINE-LINCTUS-CODEINE-ORAL-SOLUTIONS-RECLASSIFICATION-TO-PRESCRIPTION-ONLY-MEDICINE
- HSSMD-06-2024-VALPROATE-IMPORTANT-NEW-REGULATORY-MEASURE-FOR-OVERSIGHT-OF-PRESCRIBING-TO-NEW-PATIENTS-AND-EXISTING-FEMALE-PATIENTS
- HSS-MD-4-2024-Fluoroquinolone-antibiotics-and-Omega-3-acid-ethyl-ester-medicines
- CNO-Letter-to-Sector-Nursing-Officer-for-Older-People-Applications
- Nursing-Officer-for-Older-People-Secondment-Opportunity-Notice-March-2024
- HSS-MD-3-2024-MHRA-Drug-Safety-Update-–-Valproate-Belvo-Convulex-Depakote-Dyzantil-Epilim-Epilim-Chrono-or-Chronosphere-Episenta-Epival-and-Syonell
- HSSMD-02-2024-SEASONAL-INFLUENZA-VACCINATION-OFFER-TO-ALL-50-64-YEAR-OLDS-AND-ALL-HEALTH-AND-SOCIAL-CARE-WORKERS
- HSS-MD-55-2023-Addendum-MHRA-DRUG-SAFETY-UPDATE-ISOTRETINOIN-ROACCUTANE
Visit the Department of Health’s HSS(MD) Letters and urgent communications page
for more.